1460777032-d191ef25-e229-458e-a2ce-ff87ac397047

1. An animal feed composition comprising DHA from a microbial source, wherein the microbial source provides the primary source of DHA in the animal feed.
2. The composition of claim 1, wherein the microbial source of DHA is from intact cells of Crypthecodinium or Schizockytrium or lipid extracts therefrom.
3. The composition of claim 1, wherein said feed contains from about 0.01% to 1.5% DHA.
4. The composition of claim 1, wherein said feed contains from about 0.025% to 0.25% DHA.
5. The composition of claim 1, wherein the animal is selected from the group consisting of dog, cat, horse, pig, shrimp and salmon.
6.-12. (canceled)
13. The composition of claim 1, wherein the DHA dose provided to the animal is between 0.1 and 10 mg DHAkgday.
14. The composition of claim 1, wherein the DHA dose provided to the animal is between 0.5 and 5.0 mg DHAkgday.
15. The composition of claim 1, wherein the animal feed comprising DHA from a microbial source contains no animal-derived materials.
16. The composition of claim 1, wherein the animal feed comprising DHA from a microbial source contains no ethoxyquin.
17. The composition of claim 1, wherein the animal feed comprising DHA from a microbial source contains lecithin at a level of from 1-20 g lecithin20 g DHA from the microbial source
18. A method of preparing a feed comprising DHA from a microbial source, the method comprising:
culturing heterotropic microalgae containing DHA in a culture medium comprising glucose;
harvesting and centrifuging biomass comprising the microalgae to form a thick paste;
drying and grounding said biomass into a fine powder.
19. The method of claim 18, wherein the DHA from the microbial source is present at from 0.01% to 1.5% DHA.
20. The method of claim 18, wherein the DHA from the microbial source is present at from 0.025% to 0.25% DHA.
21. The method of claim 18, wherein the DHA from the microbial source is from intact cells of Crypthecodinium or Schizochytrium or lipid extracts therefrom.
22. The method of claim 18, wherein the feed is an extruded feed or supplement.
23. The method of claim 18, wherein the feed is a pelleted feed or supplement.
24. The method of claim 18, wherein the biomass comprising microbial DHA is blended with lecithin at a level of from 1-20 g lecithin20 g DHA from the microbial source.
25. A method of improving the neurological development of a young animal, the method comprising:
feeding the young animal’s mother during the period of pregnancy or lactation with a feed comprising DHA from a microbial source, wherein the microbial source provides the primary source of DHA in the animal feed.
26. The method of claim 25 wherein the animal is selected from the group consisting of dog, cat, horse, pig, shrimp and salmon.
27.-31. (canceled)
32. The method of claim 25 where the DHA from the microbial source is from intact cells of Crypthecodinium or Schizochytrium or lipid extracts therefrom.
33. A method of improving the neurological development of a young animal by the feeding it through the first 25% of its lifetime with a feed comprising DHA from a microbial source, wherein the microbial source provides the primary source of DHA in the animal feed.
34. The method of claim 33 wherein the animal is selected from the group consisting of dog, cat, horse, pig, shrimp or salmon.
35.-39. (canceled)
40. The method of claim 23 where the DHA from the microbial source is from intact cells of Crypthecodinium or Schizochytrium or lipid extracts therefrom.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of the formula (I)
wherein
one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms,
R5 and R6 together with the nitrogen between them form a saturated or unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups,
X is NH\u2014,
Y is a nitrogen atom,
or a pharmaceutically acceptable salt thereof formed with acids or bases.
2. A compound of the Formula (I) defined in claim 1 and selected from the group consisting of:
(6-hydroxy-1H-benzimidazol-2-yl)-4-(4-methyl-benzyl)-piperidine-1-ylmethanone; and
(4-benzylpiperidin-1-yl)-6-hydroxy-1H-benzimidazol-2-yl)-methanone;
or a pharmaceutically acceptable salt thereof formed with acids or bases.
3. The compound of the Formula (I) defined in claim 1 which is (4-benzylpiperidin-1-yl)-6-hydroxy-1H-benzimidazol-2-yl)-methanone or a pharmaceutically acceptable salt thereof formed with acids or bases.
4. A pharmaceutical compositions having an NR2B selective receptor antagonist effect, comprising a therapeutically effective amount of a compound of the Formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof formed with acids or bases and a pharmaceutically acceptable inert carrier.
5. A method of treating pain in a mammalian subject in need of the treatment which comprises the step of administering to the mammalian subject a therapeutically effective amount of the compound of the Formula (I) defined in claim 1.
6. A process for preparing a compound of the Formula (I)
wherein
one of the neighboring R1, R2, R3 and R4 groups is hydroxy, and the others are each hydrogen atoms,
R5 and R6 together with the nitrogen between them form a saturated or a unsaturated, 4-6 membered heterocyclic ring, which is substituted by phenoxy, phenyl-(C1-C4 alkyl), phenyl-(C1-C4 alkoxy), phenoxy-(C1-C4 alkyl), or benzoyl, optionally substituted on the aromatic ring by one or more halogen atoms, cyano or hydroxy groups, C1-C4 alkyl or C1-C4 alkoxy groups,
X is NH\u2014,
Y is a nitrogen atom,
or a pharmaceutically acceptable salt thereof formed with acids or bases, which comprises the step of:
amidating a compound of the Formula (II)
wherein the meaning of R1, R2, R3, R4, X and Y are as defined above with a compound of the Formula (III)
wherein the meaning of R5 and R6 are as defined above, to obtain the compound of the Formula (I) or a pharmaceutically acceptable salt thereof formed with an acid or a base, then the so obtained compound of formula (I) or pharmaceutically acceptable salt formed with an acid or a base is optionally transformed into another compound of the Formula (I) or pharmaceutically acceptable salt thereof formed with an acid or a base by introducing a new substituent andor by modifying or removing an existing substituent, andor by forming a pharmaceutically acceptable salt with an acid or base andor by liberating a compound of the Formula (I) from its pharmaceutically acceptable salt formed with an acid or base.
7. The process defined in claim 6, wherein the compound of the Formula (II) undergoing amidation with the compound of the Formula (III), is in the form of an active derivative of a carboxylic acid.
8. The process defined in claim 7, wherein the compound of the Formula (II) in the form of an active derivative of a carboxylic acid is an ester formed with 0-benzotriazol-1-yl-N,N,N\u2032,N\u2032-tetramethyluronium hexafluorophosphate.
9. The process defined in claim 7, wherein the compound of the Formula (II) in the form of an active derivative of a carboxylic acid is an acid halogenide.
10. The process defined in claim 9, wherein the acid halogenide is an acid chloride.